联系客服

300765 深市 新诺威


首页 公告 新诺威:2021年度财务决算报告

新诺威:2021年度财务决算报告

公告日期:2022-03-18

新诺威:2021年度财务决算报告 PDF查看PDF原文

              石药集团新诺威制药股份有限公司

                  2021 年度财务决算报告

        石药集团新诺威制药股份有限公司(以下简称“公司”)财务报表,包括 2021

    年 12 月 31 日的合并及母公司资产负债表,2021 年度的合并及母公司利润表、

    合并及母公司现金流量表、合并及母公司股东权益变动表,以及相关财务报表附

    注 已 经 信 永 中 和 会 计 师 事 务 所 ( 特 殊 普 通 合 伙 ) 审 计 , 并 出 具 了

    XYZH/2022HZAA10070 标准无保留意见的审计报告。

    一、主要财务数据和指标

                                      2021 年          2020 年      本年比上年增减      2019 年

营业收入(元)                        1,431,987,664.46  1,317,414,122.08            8.70%  1,256,502,359.88

归属于上市公司股东的净利润(元)      317,071,430.99    299,835,756.44            5.75%    273,197,126.61

归属于上市公司股东的扣除非经常性

损益的净利润(元)                    298,498,249.98    263,188,500.07            13.42%    238,465,715.95

经营活动产生的现金流量净额(元)      170,592,336.20    349,071,664.26            -51.13%    315,384,186.07

基本每股收益(元/股)                          0.581            0.549            5.83%            0.500

稀释每股收益(元/股)                          0.581            0.549            5.83%            0.500

加权平均净资产收益率                          11.29%          11.82%            -0.53%          13.77%

                                      2021 年末        2020 年末    本年末比上年末增减    2019 年末

资产总额(元)                        3,225,776,209.68  2,954,902,756.59            9.17%  2,852,373,126.14

归属于上市公司股东的净资产(元)      2,952,078,874.74  2,678,111,938.23            10.23%  2,406,399,708.49

    二、资产及负债状况

                                                                                          单位:元

                    2021 年末                  2021 年初

                            占总资产                    占总资产  比重增减        重大变动说明

                  金额        比例          金额          比例

货币资金      1,231,863,277.33  38.19%    1,138,744,787.20  38.54%      -0.35%

                                                                              主要由于第四季度末咖啡因类
应收账款      269,787,693.48    8.36%      146,270,977.17    4.95%      3.41% 产品价格上涨等原因导致期末
                                                                              应收账款余额增加。

存货          216,857,370.81    6.72%      110,998,816.18    3.76%      2.96% 主要由于海外子公司增加库存
                                                                              商品备货量以及原材料价格上

                                                                              涨等原因,分别导致原材料及
                                                                              库存商品金额增加。

长期股权投资  243,185,931.33    7.54%      235,874,486.64    7.98%      -0.44%

                                                                              主要由于公司出售河北中诺医
固定资产      466,148,503.58  14.45%      572,657,618.28  19.38%      -4.93% 药科技有限公司 100%股权,导
                                                                              致固定资产期末余额的降低。

在建工程      128,676,240.34    3.99%      154,828,065.57    5.24%      -1.25%

使用权资产        823,153.61    0.03%        1,646,307.21    0.06%      -0.03%

合同负债        17,909,145.81    0.56%      25,270,340.67    0.86%      -0.30%

租赁负债                                      840,957.77    0.03%      -0.03%

    三、2021 年度经营成果

                                                                                          单位:元

                                            2021 年                2020 年            本年比上年增减

营业收入                                    1,431,987,664.46          1,317,414,122.08                8.70%

营业成本                                      746,116,862.46            584,198,130.45                27.72%

销售费用                                      260,995,820.88            328,041,857.01              -20.44%

管理费用                                      46,655,191.97            46,769,613.16                -0.24%

财务费用                                      -20,329,036.16            11,486,789.53              -276.98%

研发费用                                      20,398,576.92            14,045,625.76                45.23%

净利润                                        316,543,536.85            299,712,195.85                5.62%

    四、2021 年度现金流分析

                                                                                          单位:元

          项目                    2021 年                    2020 年                  同比增减

经营活动现金流入小计                  1,450,551,500.14            1,489,066,662.02                    -2.59%

经营活动现金流出小计                  1,279,959,163.94            1,139,994,997.76                    12.28%

经营活动产生的现金流量净

额                                      170,592,336.20              349,071,664.26                  -51.13%

投资活动现金流入小计                  1,400,058,139.91            2,959,958,217.63                  -52.70%

投资活动现金流出小计                  1,426,917,941.82            2,613,792,516.11                  -45.41%

投资活动产生的现金流量净

额                                      -26,859,801.91              346,165,701.52                  -107.76%

筹资活动现金流出小计                    42,863,944.95              28,000,000.00                    53.09%

筹资活动产生的现金流量净

额                                      -42,863,944.95             
[点击查看PDF原文]